LUX-LUNG-6

NCT01121393 📎

Regimen

Experimental: afatinib
Control: cisplatin+gemcitabine

Population

Asian EGFR-mut advanced NSCLC

Key finding

mPFS 11.0 vs 5.6 mo, HR 0.28 (0.20-0.39); Asian afatinib 1L validation

Timeline

Enrollment start: 2010-04-19 📎

Guideline citations

NCCN NSCLC Version 5.2026 (p.112)